PL2912186T3 - Leczenie ukierunkowane na płytki krwi - Google Patents

Leczenie ukierunkowane na płytki krwi

Info

Publication number
PL2912186T3
PL2912186T3 PL13848463T PL13848463T PL2912186T3 PL 2912186 T3 PL2912186 T3 PL 2912186T3 PL 13848463 T PL13848463 T PL 13848463T PL 13848463 T PL13848463 T PL 13848463T PL 2912186 T3 PL2912186 T3 PL 2912186T3
Authority
PL
Poland
Prior art keywords
targeted treatment
platelet
platelet targeted
treatment
targeted
Prior art date
Application number
PL13848463T
Other languages
English (en)
Inventor
David A. Wilcox
Sandra L. Haberichter
Original Assignee
Platelet Targeted Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Platelet Targeted Therapeutics Llc filed Critical Platelet Targeted Therapeutics Llc
Publication of PL2912186T3 publication Critical patent/PL2912186T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL13848463T 2012-10-24 2013-10-24 Leczenie ukierunkowane na płytki krwi PL2912186T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment
EP13848463.9A EP2912186B1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Publications (1)

Publication Number Publication Date
PL2912186T3 true PL2912186T3 (pl) 2021-06-14

Family

ID=50545271

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13848463T PL2912186T3 (pl) 2012-10-24 2013-10-24 Leczenie ukierunkowane na płytki krwi

Country Status (13)

Country Link
US (3) US9982034B2 (pl)
EP (2) EP2912186B1 (pl)
JP (2) JP2016501515A (pl)
KR (1) KR101819803B1 (pl)
BR (1) BR112015009229B1 (pl)
CA (1) CA2888982C (pl)
DK (1) DK2912186T3 (pl)
ES (1) ES2854754T3 (pl)
HK (1) HK1211986A1 (pl)
IL (1) IL238417B (pl)
PL (1) PL2912186T3 (pl)
WO (1) WO2014066663A1 (pl)
ZA (1) ZA201502945B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
EP3861102A4 (en) * 2018-10-05 2022-07-13 University of Utah Research Foundation METHODS OF MAKING BOARDS COMPRISING MODIFIED RECEPTORS AND USES THEREOF
WO2020113090A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
WO2020186193A1 (en) * 2019-03-13 2020-09-17 Cellphire, Inc. Canine blood platelet preparations
BR112021021984A2 (pt) 2019-05-03 2022-03-03 Cellphire Inc Materiais e métodos para produzir produtos de sangue
BR112022002892A2 (pt) 2019-08-16 2022-05-24 Cellphire Inc Trombossomos como um agente de reversão de agente antiplaqueta
US20210308185A1 (en) 2020-02-04 2021-10-07 Cellphire, Inc. Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7184826B2 (en) 1996-06-18 2007-02-27 Alza Corporation Device and method for enhancing transdermal flux of agents being delivered or sampled
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100453132B1 (ko) 1996-12-20 2004-10-15 앨자 코포레이션 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
NZ530131A (en) * 2001-06-15 2005-12-23 Andre C Gene therapy for hemophilia A
US7629153B2 (en) * 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
AU2002347062B2 (en) 2001-10-06 2008-06-26 Merial Ltd CpG formulations and related methods
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
NZ554895A (en) 2004-11-03 2009-06-26 Almac Diagnostics Ltd Transcriptome microarray technology and methods of using the same
KR100981092B1 (ko) 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
BR112012011740A2 (pt) * 2009-11-13 2018-03-27 Grifols Therapeutics Inc polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
US20120225028A1 (en) 2011-03-02 2012-09-06 Moshe Cohen Compositions and methods for mobilization of stem cells

Also Published As

Publication number Publication date
EP2912186A1 (en) 2015-09-02
DK2912186T3 (da) 2021-02-22
JP2016501515A (ja) 2016-01-21
KR20150069017A (ko) 2015-06-22
IL238417B (en) 2019-07-31
CA2888982C (en) 2020-07-21
KR101819803B1 (ko) 2018-01-17
BR112015009229B1 (pt) 2021-07-20
IL238417A0 (en) 2015-06-30
JP2018161152A (ja) 2018-10-18
EP3859004A1 (en) 2021-08-04
ZA201502945B (en) 2016-11-30
US20180009874A1 (en) 2018-01-11
ES2854754T3 (es) 2021-09-22
HK1211986A1 (en) 2016-06-03
BR112015009229A2 (pt) 2017-11-14
EP2912186B1 (en) 2021-01-06
US20190270791A1 (en) 2019-09-05
WO2014066663A1 (en) 2014-05-01
JP6975105B2 (ja) 2021-12-01
US20150344541A1 (en) 2015-12-03
EP2912186A4 (en) 2016-06-08
US9982034B2 (en) 2018-05-29
CA2888982A1 (en) 2014-05-01
US10294291B2 (en) 2019-05-21

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
EP2916795A4 (en) IMPROVED ROLLATOR
EP2819703A4 (en) TREATMENT OF PAIN
EP2921192A4 (en) CATHETER
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
EP2823767A4 (en) CATHETER
EP2862620A4 (en) SYSTEM FOR TREATING DISCHARGE GAS
EP2926857A4 (en) CATHETER
HK1211986A1 (en) Platelet targeted treatment
GB2521289B (en) Formation treatment system
GB201217439D0 (en) Combination therapy
EP2777576A4 (en) TREATMENT SYSTEM
EP2803328A4 (en) TREATMENT SYSTEM
EP2789306A4 (en) TREATMENT SYSTEM
EP2864362A4 (en) ANTICANCER TREATMENT
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
EP2810680A4 (en) CATHETER
EP2804853A4 (en) THERAPEUTIC USES
EP2704731A4 (en) TREATMENT OF AVIAN ORIGIN
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
EP2900310A4 (en) MULTI-WINDING CATHETER